Lucid Diagnostics Expands Direct Contracting Initiative with Multiple Programs Focused on Near-Term Revenue Drivers [Yahoo! Finance]
Lucid Diagnostics Inc. (LUCD)
Company Research
Source: Yahoo! Finance
NEW YORK Nov. 5, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that its commercial team has embarked on an expansion of its direct contracting initiative, focusing on programs designed to drive near-term EsoGuard ® Esophageal DNA Test revenue, complementing ongoing efforts in traditional reimbursement. These programs include fully-contracted #CheckYourFoodTube Precancer Testing Events, Concierge Medicine, and Employer Markets. To support these initiatives, Lucid has hired two seasoned professionals from GRAIL, Inc., who have successfully driven revenue from the Galleri ® multi-cancer early detection test in similar programs. "Following the recent explosion in our clinical evidence base for EsoGuard esophageal precancer testing, our team carefully explored new opportunities to expand our commercial strategy while we
Show less
Read more
Impact Snapshot
Event Time:
LUCD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LUCD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LUCD alerts
High impacting Lucid Diagnostics Inc. news events
Weekly update
A roundup of the hottest topics
LUCD
News
- Lucid Diagnostics Submits Clinical Evidence Package to MolDX Seeking Medicare Coverage for EsoGuard® Esophageal DNA TestPR Newswire
- Lucid Diagnostics to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services ForumPR Newswire
- Lucid Diagnostics Inc. (NASDAQ: LUCD) had its price target lowered by analysts at Cantor Fitzgerald from $3.00 to $2.00. They now have an "overweight" rating on the stock.MarketBeat
- Lucid Diagnostics Inc. (NASDAQ: LUCD) had its "buy" rating re-affirmed by analysts at Canaccord Genuity Group Inc.. They now have a $3.00 price target on the stock.MarketBeat
- Lucid Diagnostics Inc. (NASDAQ: LUCD) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $2.50 price target on the stock.MarketBeat
LUCD
Earnings
- 11/13/24 - Miss
LUCD
Sec Filings
- 11/18/24 - Form 8-K
- 11/13/24 - Form 8-K
- 11/12/24 - Form 10-Q
- LUCD's page on the SEC website